These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 34849271)
21. Unraveling neuronal ceroid lipofuscinosis type 2 (CLN2) disease: A tertiary center experience for determinants of diagnostic delay. Ardicli D; Haliloglu G; Gocmen R; Gunbey C; Topcu M Eur J Paediatr Neurol; 2021 Jul; 33():94-98. PubMed ID: 34119739 [TBL] [Abstract][Full Text] [Related]
22. A novel c.776_777insA mutation in CLN1 leads to infantile neuronal ceroid lipofuscinosis. Miller JN; Pearce DA J Child Neurol; 2013 Sep; 28(9):1106-11. PubMed ID: 23857568 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies. Topçu M; Tan H; Yalnizoğlu D; Usubütün A; Saatçi I; Aynaci M; Anlar B; Topaloğlu H; Turanli G; Köse G; Aysun S Turk J Pediatr; 2004; 46(1):1-10. PubMed ID: 15074367 [TBL] [Abstract][Full Text] [Related]
24. Pre- and postnatal diagnosis of patients with CLN1 and CLN2 by assay of palmitoyl-protein thioesterase and tripeptidyl-peptidase I activities. Young EP; Worthington VC; Jackson M; Winchester BG Eur J Paediatr Neurol; 2001; 5 Suppl A():193-6. PubMed ID: 11588996 [TBL] [Abstract][Full Text] [Related]
26. Pediatric onset neuronal ceroid lipofuscinoses: Unraveling clinical and genetic specifications. Ahdi SG; Alvi JR; Ashfaq A; Sultan T Pak J Med Sci; 2024 Sep; 40(8):1638-1643. PubMed ID: 39281238 [TBL] [Abstract][Full Text] [Related]
27. Infantile neuronal ceroid lipofuscinosis (CLN1): linkage disequilibrium in the Finnish population and evidence that variant late infantile form (variant CLN2) represents a nonallelic locus. Järvelä I Genomics; 1991 Jun; 10(2):333-7. PubMed ID: 2071142 [TBL] [Abstract][Full Text] [Related]
29. Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dozières-Puyravel B; Nasser H; Elmaleh-Bergès M; Lopez Hernandez E; Gelot A; Ilea A; Delanoë C; Puech JP; Caillaud C; Pichard S; Auvin S Dev Med Child Neurol; 2020 Apr; 62(4):528-530. PubMed ID: 31489614 [TBL] [Abstract][Full Text] [Related]
30. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720 [TBL] [Abstract][Full Text] [Related]
31. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Lu JY; Nelvagal HR; Wang L; Birnbaum SG; Cooper JD; Hofmann SL Mol Genet Metab; 2015; 116(1-2):98-105. PubMed ID: 25982063 [TBL] [Abstract][Full Text] [Related]
32. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models. Sohar I; Sleat DE; Jadot M; Lobel P J Neurochem; 1999 Aug; 73(2):700-11. PubMed ID: 10428067 [TBL] [Abstract][Full Text] [Related]